<DOC>
	<DOCNO>NCT00664573</DOCNO>
	<brief_summary>To observe long-term treatment BG9924 administer participant RA previously participate Biogen Idec Study .</brief_summary>
	<brief_title>104RA204 Assessment Safety Efficacy BG9924 Rheumatoid Arthritis ( RA ) Participants</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Must participant Study 104RA202 ( NCT 00664716 ) Stable dose Methotrexate duration study Participants significant change medical history previous BG9924 study Any clinically significant infectious illness serious local infection NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Baminercept alfa</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>BG9924</keyword>
	<keyword>Efficacy</keyword>
</DOC>